DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

ProductUpdated on 28 April 2026

Nanobody-based biologics

Nicolás Galmarini

CEO & Co-founder at NanoVet Biotech

Pamplona, Spain

About

NanoVet develops nanobody-based biologics for veterinary therapeutics, with a pipeline focused on high-burden chronic diseases, including canine atopic dermatitis, osteoarthritis, cancer immunotherapy and otherrs. Our platform leverages the unique properties of VHH antibodies, including high stability, strong tissue penetration, and cost-efficient manufacturing, enabling differentiated approaches compared to monoclonal antibodies, including multi-specific designs and alternative delivery strategies

Similar opportunities